616 related articles for article (PubMed ID: 31569425)
1. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
4. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
5. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
6. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
7. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
9. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
10. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies.
Hasselluhn MC; Schlösser D; Versemann L; Schmidt GE; Ulisse M; Oschwald J; Zhang Z; Hamdan F; Xiao H; Kopp W; Spitalieri J; Kellner C; Schneider C; Reutlinger K; Nagarajan S; Steuber B; Sastra SA; Palermo CF; Appelhans J; Bohnenberger H; Todorovic J; Kostyuchek I; Ströbel P; Bockelmann A; König A; Ammer-Herrmenau C; Schmidleitner L; Kaulfuß S; Wollnik B; Hahn SA; Neesse A; Singh SK; Bastians H; Reichert M; Sax U; Olive KP; Johnsen SA; Schneider G; Ellenrieder V; Hessmann E
Gastroenterology; 2024 Feb; 166(2):298-312.e14. PubMed ID: 37913894
[TBL] [Abstract][Full Text] [Related]
11. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
12. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
13. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.
Yao H; Song W; Cao R; Ye C; Zhang L; Chen H; Wang J; Shi Y; Li R; Li Y; Liu X; Zhou X; Shao R; Li L
Nat Commun; 2022 Sep; 13(1):5506. PubMed ID: 36127339
[TBL] [Abstract][Full Text] [Related]
14. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
15. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
17. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
18. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
19. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
